STO · FLUI.ST
Fluicell AB (publ)
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
Loading market information…
STO · QUIA.ST · SEK
Stock price, dividends, earnings
Quote as of Dec 15, 2025, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Quia Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Quia Pharma AB (publ)’s forward annual dividend is SEK 239.15 per share, paid annual. The forward yield is 47,829,230.0% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Quia Pharma AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Quia Pharma AB specializes in the research, development, and commercialization of advanced drug delivery systems. Its core product, Uni-Qleaver®, utilizes a pioneering releasable pegylation technology. This innovative approach effectively mitigates common drawbacks and allows for the precise modulation of a drug's half-life. The company, established by Marek Kwiatkowski, is headquartered in Uppsala, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 0.01+SEK 0.00 (+6.98%)
Spermosens AB’s quoted price sits in the upper half of its reported 52-week range, 23.33% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.02+SEK 0.00 (+16.48%)
Gabather AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 75.2% below the high.
SEK 0.27SEK 0.00 (0.0%)
Aptahem AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 86.21% below the high.
SEK 0.00+SEK 0.00 (0.0%)
S2Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.0% below the high.
SEK 0.02SEK 0.00 (0.0%)
LIDDS AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.7% below the high.
SEK 0.21-SEK 0.12 (-35.15%)
ProstaLund AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.2% below the high.
